26345388 Preclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury. [StringElement('To characterize the preclinical safety profile of a human embryonic stem cell-derived oligodendrocyte progenitor cell therapy product (AST-OPC1) in support of its use as a treatment for spinal cord injury (SCI).', attributes={'NlmCategory': 'OBJECTIVE', 'Label': 'AIM'}), StringElement('The phenotype and functional capacity of AST-OPC1 was characterized in vitro and in vivo. Safety and toxicology of AST-OPC1 administration was assessed in rodent models of thoracic SCI.', attributes={'NlmCategory': 'METHODS', 'Label': 'MATERIALS & METHODS'}), StringElement('These results identify AST-OPC1 as an early-stage oligodendrocyte progenitor population capable of promoting neurite outgrowth in vitro and myelination in vivo. AST-OPC1 administration did not cause any adverse clinical observations, toxicities, allodynia or tumors.', attributes={'NlmCategory': 'RESULTS', 'Label': 'RESULTS'}), StringElement('These results supported initiation of a Phase I clinical trial in patients with sensorimotor complete thoracic SCI.', attributes={'NlmCategory': 'CONCLUSIONS', 'Label': 'CONCLUSION'})] 